These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 18431733)
21. A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity. Richichi B; Thomas B; Fiore M; Bosco R; Qureshi H; Nativi C; Renaudet O; BenMohamed L Angew Chem Int Ed Engl; 2014 Oct; 53(44):11917-20. PubMed ID: 25168881 [TBL] [Abstract][Full Text] [Related]
22. Evidence for participation of RNA 1-encoded elicitor in Cowpea mosaic virus-mediated concurrent protection. Bruening G; Buzayan JM; Ferreiro C; Lim W Virology; 2000 Jan; 266(2):299-309. PubMed ID: 10639316 [TBL] [Abstract][Full Text] [Related]
23. The unique potency of Cowpea mosaic virus (CPMV) Shukla S; Wang C; Beiss V; Cai H; Washington T; Murray AA; Gong X; Zhao Z; Masarapu H; Zlotnick A; Fiering S; Steinmetz NF Biomater Sci; 2020 Sep; 8(19):5489-5503. PubMed ID: 32914796 [TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. McLain L; Porta C; Lomonossoff GP; Durrani Z; Dimmock NJ AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579 [TBL] [Abstract][Full Text] [Related]
25. Position-dependent processing of peptides presented on the surface of cowpea mosaic virus. Taylor KM; Porta C; Lin T; Johnson JE; Barker PJ; Lomonossoff GP Biol Chem; 1999 Mar; 380(3):387-92. PubMed ID: 10223342 [TBL] [Abstract][Full Text] [Related]
27. Cowpea mosaic virus: from the presentation of antigenic peptides to the display of active biomaterials. Chatterji A; Burns LL; Taylor SS; Lomonossoff GP; Johnson JE; Lin T; Porta C Intervirology; 2002; 45(4-6):362-70. PubMed ID: 12602357 [TBL] [Abstract][Full Text] [Related]
28. A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection. Zhao Z; Ortega-Rivera OA; Chung YH; Simms A; Steinmetz NF J Mater Chem B; 2023 Jun; 11(24):5429-5441. PubMed ID: 36861401 [TBL] [Abstract][Full Text] [Related]
29. On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Ragupathi G; Coltart DM; Williams LJ; Koide F; Kagan E; Allen J; Harris C; Glunz PW; Livingston PO; Danishefsky SJ Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13699-704. PubMed ID: 12359877 [TBL] [Abstract][Full Text] [Related]
30. Cowpea Mosaic Virus and Natural Killer Cell Agonism for In Situ Cancer Vaccination. Koellhoffer EC; Steinmetz NF Nano Lett; 2022 Jul; 22(13):5348-5356. PubMed ID: 35713326 [TBL] [Abstract][Full Text] [Related]
31. Direct imaging of interactions between an icosahedral virus and conjugate F(ab) fragments by cryoelectron microscopy and X-ray crystallography. Porta C; Wang G; Cheng H; Chen Z; Baker TS; Johnson JE Virology; 1994 Nov; 204(2):777-88. PubMed ID: 7941346 [TBL] [Abstract][Full Text] [Related]
32. Capillary zone electrophoresis of Cowpea mosaic virus and peak identification. Liang S; Schneider RJ Electrophoresis; 2009 May; 30(9):1572-8. PubMed ID: 19343726 [TBL] [Abstract][Full Text] [Related]
33. Inactivated Cowpea Mosaic Virus for In Situ Vaccination: Differential Efficacy of Formalin vs UV-Inactivated Formulations. Jung E; Mao C; Bhatia M; Koellhoffer EC; Fiering SN; Steinmetz NF Mol Pharm; 2023 Jan; 20(1):500-507. PubMed ID: 36399598 [TBL] [Abstract][Full Text] [Related]
34. RNA and capsid accumulation in cowpea protoplasts that are resistant to cowpea mosaic virus strain SB. Kiefer MC; Bruening G; Russell ML Virology; 1984 Sep; 137(2):371-81. PubMed ID: 6485253 [TBL] [Abstract][Full Text] [Related]
35. In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade. Mao C; Beiss V; Ho GW; Fields J; Steinmetz NF; Fiering S J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460333 [TBL] [Abstract][Full Text] [Related]
36. Glycosylation of the capsid proteins of cowpea mosaic virus: a reinvestigation shows the absence of sugar residues. Altmann F; Lomonossoff GP J Gen Virol; 2000 Apr; 81(Pt 4):1111-4. PubMed ID: 10725439 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Virus-Like Particle-Based Tumor-Associated Carbohydrate Immunogen in a Mouse Tumor Model. Sungsuwan S; Wu X; Huang X Methods Enzymol; 2017; 597():359-376. PubMed ID: 28935111 [TBL] [Abstract][Full Text] [Related]
38. The structures of a naturally empty cowpea mosaic virus particle and its genome-containing counterpart by cryo-electron microscopy. Hesketh EL; Meshcheriakova Y; Thompson RF; Lomonossoff GP; Ranson NA Sci Rep; 2017 Apr; 7(1):539. PubMed ID: 28373698 [TBL] [Abstract][Full Text] [Related]
39. Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Wu J; Guo Z Bioconjug Chem; 2006; 17(6):1537-44. PubMed ID: 17105234 [TBL] [Abstract][Full Text] [Related]
40. Cowpea mosaic virus nanoparticles for cancer imaging and therapy. Beatty PH; Lewis JD Adv Drug Deliv Rev; 2019 May; 145():130-144. PubMed ID: 31004625 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]